Filipe Nery
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Filipe Nery has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
Diana Valadares
Porto, Portugal
4 shared publications- Pierre-Emmanuel Rautou
Université Paris-Cité, Inserm, Centre de recherche sur l’inflammation, UMR 1149, Paris, France
4 shared publications Dominique Valla
Service d'Hépatologie, Hôpital Beaujon, Clichy, France; Centre de Recherche de l'Inflammation, Inserm and Université Paris Diderot, Paris, France
3 shared publications- Dominique Valla
Université Paris Cité and Inserm, Paris, France
3 shared publications Manuel Teixeira Gomes
Porto, Portugal
3 shared publicationsAndrea De Gottardi
University Clinic for Visceral Surgery and Medicine, Inselspital, Bern, Switzerland; Department of Biomedical Research, University of Bern, Bern, Switzerland
2 shared publications
Latest Publications
- 23 August 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (1) , 72-83
Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome
- 23 August 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (1) , 72-83
Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome
- Open Access
- 4 May 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (8) , 100785
Use of albumin infusion for cirrhosis-related complications: An international position statement
- 4 May 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (8) , 100785
Open AccessUse of albumin infusion for cirrhosis-related complications: An international position statement
- Open Access
- 7 July 2021
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- Vol. 29 (4) , 284-290
Dorfman-Chanarin Syndrome: A Rare Cause of Metabolic Associated Fatty Liver Disease Related to Homozygosity of the Nonsense Mutation c.934C>T (p.R312*)
Metabolic associated fatty liver disease became the most common form of chronic liver disease, in the vast majority of the cases related to increased insulin resistance or metabolic dysregulation. Yet, other causes may be implied. We report the late diagnosis of Dorfman-Chanarin syndrome in a non-alcoholic steatohepatitis previously labeled cirrhotic middle-aged man, with consanguineous parents, complicated with hepatocellular carcinoma. Congenital ichthyosis, neurosensory hearing loss and elevated muscular enzymes hit on the track of Dorfman-Chanarin syndrome. The genetic analysis uncovered a first-time described homozygotic nonsense mutation in the ABHD5 gene, responsible for coding the ABHD5 protein. The patient was successfully submitted to liver transplantation. Inborn errors of metabolism are a rare cause of metabolic associated fatty liver disease, but they need to be kept in consideration in all patients who present with atypical clinical features. This shall raise the awareness of physicians to rare forms of presentation since it may imply not only a different prognosis, but also other actions, like particular therapies as liver transplantation due to related complications of cirrhosis, or familial screening.
- 7 July 2021
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- Vol. 29 (4) , 284-290
Open AccessDorfman-Chanarin Syndrome: A Rare Cause of Metabolic Associated Fatty Liver Disease Related to Homozygosity of the Nonsense Mutation c.934C>T (p.R312*)
Metabolic associated fatty liver disease became the most common form of chronic liver disease, in the vast majority of the cases related to increased insulin resistance or metabolic dysregulation. Yet, other causes may be implied. We report the late diagnosis of Dorfman-Chanarin syndrome in a non-alcoholic steatohepatitis previously labeled cirrhotic middle-aged man, with consanguineous parents, complicated with hepatocellular carcinoma. Congenital ichthyosis, neurosensory hearing loss and elevated muscular enzymes hit on the track of Dorfman-Chanarin syndrome. The genetic analysis uncovered a first-time described homozygotic nonsense mutation in the ABHD5 gene, responsible for coding the ABHD5 protein. The patient was successfully submitted to liver transplantation. Inborn errors of metabolism are a rare cause of metabolic associated fatty liver disease, but they need to be kept in consideration in all patients who present with atypical clinical features. This shall raise the awareness of physicians to rare forms of presentation since it may imply not only a different prognosis, but also other actions, like particular therapies as liver transplantation due to related complications of cirrhosis, or familial screening.
- 21 May 2021
- Published by Springer Nature
- p. 23-27
Epidemiology of Portal Vein Thrombosis
- Open Access
- 27 May 2020
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- Vol. 28 (1) , 62-66
Budd-Chiari Syndrome and Acute Liver Failure: An Uncommon Presentation of Acute Myeloid Leukaemia
Acute liver failure (ALF) is a rare entity, particularly in the context of Budd-Chiari syndrome (BCS). BCS is an uncommon disorder with multiple risk factors, most commonly myeloproliferative disorders. In BCS, active search and exclusion of underlying malignancy is mandatory, particularly in the context of ALF, as it may contraindicate liver transplantation (LT). We present the case of a healthy 29-year-old male, without known risk factors for liver disease, who presented to the emergency department with abdominal pain, ascites, and jaundice. BCS with consequent severe acute liver injury with rapid progression to ALF was diagnosed. The patient was listed for LT. The study of peripheral blood finally revealed myeloid blasts, and flow cytometry showed a population of blast cells with abnormal immunophenotypic profile (CD33+ and myeloperoxidase, MPO+). The bone marrow biopsy showed morphological and immunophenotypic aspects of acute myeloid leukaemia (AML) FAB M1. This diagnosis was considered a formal contraindication to LT, so the patient was delisted. ALF contraindicated rescue chemotherapy and AML contraindicated LT. The patient died 48 h after ICU admission. The search for underlying neoplasia is mandatory in the context of BCS, moreover with associated ALF, as it may limit lifesaving treatments and interventions to supportive and palliative care.
- 27 May 2020
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- Vol. 28 (1) , 62-66
Open AccessBudd-Chiari Syndrome and Acute Liver Failure: An Uncommon Presentation of Acute Myeloid Leukaemia
Acute liver failure (ALF) is a rare entity, particularly in the context of Budd-Chiari syndrome (BCS). BCS is an uncommon disorder with multiple risk factors, most commonly myeloproliferative disorders. In BCS, active search and exclusion of underlying malignancy is mandatory, particularly in the context of ALF, as it may contraindicate liver transplantation (LT). We present the case of a healthy 29-year-old male, without known risk factors for liver disease, who presented to the emergency department with abdominal pain, ascites, and jaundice. BCS with consequent severe acute liver injury with rapid progression to ALF was diagnosed. The patient was listed for LT. The study of peripheral blood finally revealed myeloid blasts, and flow cytometry showed a population of blast cells with abnormal immunophenotypic profile (CD33+ and myeloperoxidase, MPO+). The bone marrow biopsy showed morphological and immunophenotypic aspects of acute myeloid leukaemia (AML) FAB M1. This diagnosis was considered a formal contraindication to LT, so the patient was delisted. ALF contraindicated rescue chemotherapy and AML contraindicated LT. The patient died 48 h after ICU admission. The search for underlying neoplasia is mandatory in the context of BCS, moreover with associated ALF, as it may limit lifesaving treatments and interventions to supportive and palliative care.
- 1 May 2019
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 4 (5) , 399-411
Porto-sinusoidal vascular disease: proposal and description of a novel entity
- 1 May 2019
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 4 (5) , 399-411
Porto-sinusoidal vascular disease: proposal and description of a novel entity
- Open Access
- 23 April 2019
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 49 (10) , 1371-1372
Letter: nonselective beta‐blockers, endoscopic therapy and portal vein thrombosis in cirrhosis. Authors' reply
Linked ContentThis article is linked to Nery et al and Bosch and Berzigotti papers. To view these articles, visit https://doi.org/10.1111/apt.15137 and https://doi.org/10.1111/apt.15236.
- 23 April 2019
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 49 (10) , 1371-1372
Open AccessLetter: nonselective beta‐blockers, endoscopic therapy and portal vein thrombosis in cirrhosis. Authors' reply
Linked ContentThis article is linked to Nery et al and Bosch and Berzigotti papers. To view these articles, visit https://doi.org/10.1111/apt.15137 and https://doi.org/10.1111/apt.15236.
- Open Access
- 22 January 2019
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 49 (5) , 582-588
Nonselective beta‐blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study
Summary: Background: Nonmalignant portal vein thrombosis is a significant event in the course of cirrhosis that can contraindicate liver transplantation and even impact survival after the surgical procedure. Risk factors are not completely known or validated and are still debated.Aim: To identify in patients with cirrhosis the risk factors for portal vein thrombosis that are assessable in clinical practice.Methods: Between January 2014 and February 2017, 108 outpatients with cirrhosis and no portal vein thrombosis (78% Child A) were enrolled. Doppler ultrasound was performed every 3 or 6 months, for a median follow up of 19 months.Results: Portal vein thrombosis developed in 11 patients. Nonselective beta‐blockade (hazard ratio [HR] 10.56; 95% confidence interval [CI]: 1.35‐82.73; P = 0.025), and medium or large‐sized oesophageal varices (HR 5.67; 95% CI: 1.49‐21.63; P = 0.011) at baseline were associated with portal vein thrombosis development. Although heart rate (P < 0.001) and portal blood flow velocity at baseline (P = 0.005) were significantly reduced by nonselective beta‐blockers, they were not related to portal vein thrombosis development.Conclusions: Our findings confirm an association between portal vein thrombosis development and oesophageal varices at baseline, but suggest that the association could be explained by exposure to nonselective beta‐blockers, independently from effects on heart rate and portal blood flow velocity. The mechanisms that explain portal vein thrombosis development in patients on nonselective beta‐blockers require elucidation in order to optimise targeting of nonselective beta‐blockade in patients with cirrhosis.
- 22 January 2019
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 49 (5) , 582-588
Open AccessNonselective beta‐blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study
Summary: Background: Nonmalignant portal vein thrombosis is a significant event in the course of cirrhosis that can contraindicate liver transplantation and even impact survival after the surgical procedure. Risk factors are not completely known or validated and are still debated.Aim: To identify in patients with cirrhosis the risk factors for portal vein thrombosis that are assessable in clinical practice.Methods: Between January 2014 and February 2017, 108 outpatients with cirrhosis and no portal vein thrombosis (78% Child A) were enrolled. Doppler ultrasound was performed every 3 or 6 months, for a median follow up of 19 months.Results: Portal vein thrombosis developed in 11 patients. Nonselective beta‐blockade (hazard ratio [HR] 10.56; 95% confidence interval [CI]: 1.35‐82.73; P = 0.025), and medium or large‐sized oesophageal varices (HR 5.67; 95% CI: 1.49‐21.63; P = 0.011) at baseline were associated with portal vein thrombosis development. Although heart rate (P < 0.001) and portal blood flow velocity at baseline (P = 0.005) were significantly reduced by nonselective beta‐blockers, they were not related to portal vein thrombosis development.Conclusions: Our findings confirm an association between portal vein thrombosis development and oesophageal varices at baseline, but suggest that the association could be explained by exposure to nonselective beta‐blockers, independently from effects on heart rate and portal blood flow velocity. The mechanisms that explain portal vein thrombosis development in patients on nonselective beta‐blockers require elucidation in order to optimise targeting of nonselective beta‐blockade in patients with cirrhosis.
- Open Access
- 10 September 2018
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- Vol. 26 (4) , 275-278
Improvement of Central Nervous System Vasculitis in a Patient with Chronic Hepatitis C Virus Infection after Treatment with an Interferon-Free Regimen
Background: Neurosarcoidosis is a rare manifestation of hepatitis C virus (HCV) infection, mainly in patients exposed to interferon-based therapies. Although we are living in a new era of HCV treatment, there is still little data concerning the treatment of extrahepatic complications of the disease with direct antiviral agents, especially rare ones such as neurosarcoidosis. Summary: We present a rare case of central nervous system vasculitic lesions in the context of chronic HCV infection associated with mixed cryoglobulinemia, elevated angiotensin-converting enzyme (ACE) levels, and documentation of viral RNA in the cerebrospinal fluid in a treatment-naïve chronic HCV patient. Successful treatment with an interferon-free regimen improved all clinical manifestations, reduced the levels of serum ACE, and reduced the cryoglobulin levels to undetectable. Messages: Neurosarcoidosis and cryoglobulinemia are rare but well-recognized complications of HCV infection, even in treatment-naïve patients. Direct antiviral agents can be useful in the management of this condition.
- 10 September 2018
- Published by S. Karger AG in GE - Portuguese Journal of Gastroenterology
- Vol. 26 (4) , 275-278
Open AccessImprovement of Central Nervous System Vasculitis in a Patient with Chronic Hepatitis C Virus Infection after Treatment with an Interferon-Free Regimen
Background: Neurosarcoidosis is a rare manifestation of hepatitis C virus (HCV) infection, mainly in patients exposed to interferon-based therapies. Although we are living in a new era of HCV treatment, there is still little data concerning the treatment of extrahepatic complications of the disease with direct antiviral agents, especially rare ones such as neurosarcoidosis. Summary: We present a rare case of central nervous system vasculitic lesions in the context of chronic HCV infection associated with mixed cryoglobulinemia, elevated angiotensin-converting enzyme (ACE) levels, and documentation of viral RNA in the cerebrospinal fluid in a treatment-naïve chronic HCV patient. Successful treatment with an interferon-free regimen improved all clinical manifestations, reduced the levels of serum ACE, and reduced the cryoglobulin levels to undetectable. Messages: Neurosarcoidosis and cryoglobulinemia are rare but well-recognized complications of HCV infection, even in treatment-naïve patients. Direct antiviral agents can be useful in the management of this condition.
- 24 October 2017
- Published by BMJ in BMJ Case Reports
- Vol. 2017
Acute hepatitis B virus infection and severe non-immune haemolytic anaemia: a rare relationship
The clinical presentation of acute hepatitis B virus (HBV) infection is usually related to the onset of liver failure and damage. Anaemia may occur, but it is only rarely attributed to haemolysis. The authors report about the case of a 41-year-old woman with the diagnosis of acute HBV infection and coagulopathy (without encephalopathy) who developed non-immune haemolytic anaemia. Total recovery of the analytical liver profile, coagulopathy and anaemia was achieved through treatment targeting HBV.This case shows that, although rare, non-immune haemolytic anaemia may occur in association with acute HBV infection and that HBV suppression seems to lead to progressive anaemia resolution.
- 24 October 2017
- Published by BMJ in BMJ Case Reports
- Vol. 2017
Acute hepatitis B virus infection and severe non-immune haemolytic anaemia: a rare relationship
The clinical presentation of acute hepatitis B virus (HBV) infection is usually related to the onset of liver failure and damage. Anaemia may occur, but it is only rarely attributed to haemolysis. The authors report about the case of a 41-year-old woman with the diagnosis of acute HBV infection and coagulopathy (without encephalopathy) who developed non-immune haemolytic anaemia. Total recovery of the analytical liver profile, coagulopathy and anaemia was achieved through treatment targeting HBV.This case shows that, although rare, non-immune haemolytic anaemia may occur in association with acute HBV infection and that HBV suppression seems to lead to progressive anaemia resolution.